Project Grant HT94252310794
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$493K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $713,689 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, effective September 1, 2023, will support UT Southwestern's research to leverage biophysicochemical motifs in T-cell receptor antigen binding regions and antigen co-occurrence to predict response to immune checkpoint inhibitors. The grant provides funding for basic...
The Defense Health Agency awarded a $1.1 million project grant to the University of Texas Southwestern Medical Center in Dallas, Texas, to support research under the Military Medical Research and Development program. The three-year award beginning in June 2023 will fund the development of a multifunctional immunotherapy nanoparticle to enable innate immunotherapy for kidney cancer. As the prime awardee, UT Southwestern will leverage its expertise in oncology and immunology to advance this...
The Defense Health Agency awarded a $725,000 project grant to The University of Texas Southwestern Medical Center in Dallas, Texas, for research under the Military Medical Research and Development program. The three-year award beginning June 15, 2023, will support research into glutamine-targeted therapies to prevent traumatic heterotopic ossification. As the parent organization, the University of Texas System will provide research support services through this subaward. The Military Medical...
The University of Texas Southwestern Medical Center was awarded a $2,641,871 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from May 1, 2023 through April 30, 2027 to comprehensively upregulate and stabilize frataxin mRNA using antisense oligonucleotides. The goal of this research is to transform health care for service members and the public by investigating medical solutions for the...
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $766,965 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on June 30, 2024. The grant supports a 3-year research project to develop new methods for targeting kidney cancer tumors in order to improve immunotherapy outcomes. The research aims to identify tumor surface biomarkers that can be leveraged to enhance the effectiveness of cancer...
The University of Texas Southwestern Medical Center was awarded a $1,467,321 project grant from the Defense Health Agency under the Military Medical Research and Development program. The grant will fund research from August 1, 2023 to July 31, 2026 to investigate the mechanisms controlling the progression of prostate adenocarcinoma to neuroendocrine cancer. As part of its mission to transform military and public health through innovative medical research solutions, the Defense Health Agency...
The federal Project Grant award in the amount of $1,312,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to The University of Texas Southwestern Medical Center in Dallas, TX to "DEFINE THE HUMORAL IMMUNITY IN KIDNEY CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS." The grant has a performance period from September 1, 2024 to August 31, 2028 and supports advanced biomedical research...
The Defense Health Agency awarded a $1,107,001 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) to conduct research on the DROSHA gene's role in regulating mesenchymal expression and chemosensitivity in Wilms tumor. The grant was awarded on September 30, 2023 and will run through September 29, 2026 under the Military Medical Research and Development program (CFDA 12.420). UT Southwestern, a component of the University of Texas System, will lead the...
This Project Grant award of $1,106,902.00 was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award supports research at the University of Texas Southwestern Medical Center in Dallas, Texas to "delineate tumor-immune contexture that shapes clear cell renal cell carcinoma (ccRCC) metastatic progression and response to immunotherapy." The 3-year project aims to advance the understanding of the tumor-immune...